---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-005020"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:33:17.385844+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Korro Bio dosed first participants in Phase 1/2a study of KRRO-110 for AATD; interim data H2 2025

## Summary
- First participants dosed in REWRITE Phase 1/2a study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD).
- Interim data from Part 1 (single ascending doses) expected H2 2025; study completion anticipated in 2026.
- Pipeline update: Korro targets 3 candidates, 2 tissue types, single platform (3-2-1 strategy) by 2027.
- Novo Nordisk partnered program in cardiometabolic indication progressing towards clinic.

## SEC filing metadata
- accession: 0001193125-25-005020
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312525005020/0001193125-25-005020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312525005020/d915237d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-005020
- JSON: https://secwatch.observer/filing/0001193125-25-005020.json
- Plain text: https://secwatch.observer/filing/0001193125-25-005020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.